The report covers forecast and analysis for the osteoporosis drugs market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based revenue (USD Billion). The study includes drivers and restraints for the osteoporosis drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the osteoporosis drugs market on a global level.
In order to give the users of this report a comprehensive view on the osteoporosis drugs market, we have to include competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class segments and gender segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research& development, drug class and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, drug class portfolio of various companies along with patent analysis (2011-2016) bifurcated into the patent trend, patent share by company and patent analysis according to the region.
The study provides a decisive view on the osteoporosis drugs market by segmenting the market based on drug class, gender, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Based on drug class the market is segmented into bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs). Key gender market covered under this study includes male and female. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East & Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for osteoporosis drugs based on individual drug class and gender in all the regions and countries.
The report also includes detailed profiles of end players such as Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.
This report segments the global osteoporosis drugs market as follows:
Global Osteoporosis Drugs Market: Drug Class Segment Analysis
- Rank Ligand Inhibitors
- Parathyroid Hormone Therapy (PTH)
- Selective Estrogen Receptor Modulators (SERMs)
Global Osteoporosis Drugs Market: Gender Segment Analysis
Global Osteoporosis Drugs Market: Regional Segment Analysis
- North America
- Asia Pacific
- Latin America
- Middle East and Africa